Eledon Pharmaceuticals Inc (ELDN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Eledon Pharmaceuticals Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Eledon Pharmaceuticals Inc (ELDN) has returned 103.97% so far this year and -9.14% over the past 12 months. Over the last ten years, ELDN has returned -43.53% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Sep 17, 2014, ELDN's average daily return is -0.04%, while the average monthly return is -0.49%.

Historically, 40% of months were positive and 60% were negative. The best month was Jan 2019 with a return of +168.8%, while the worst month was Jul 2016 at -77.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, ELDN closed higher 44% of trading days. The best single day was Sep 15, 2020 with a return of +192.9%, while the worst single day was Jul 26, 2016 at -78.9%.

Eledon Pharmaceuticals Inc has an annualized alpha of -17.26%, beta of 0.70, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 18, 2014.

• This stock participated in 152.46% of S&P 500 Index downside but only -86.29% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ELDN ranks 39 for risk / return — below 39% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Eledon Pharmaceuticals Inc (ELDN) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Eledon Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Eledon Pharmaceuticals Inc was 99.97%, occurring on Nov 29, 2023. The portfolio has not yet recovered.

The current Eledon Pharmaceuticals Inc drawdown is 99.92%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Eledon Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Eledon Pharmaceuticals Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.